ArticleAddiction science & clinical practice2026
Prescribing to protect case series: naltrexone as a novel intervention to prevent fentanyl overdose in people who use cocaine.
Article in Addiction science & clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe rise in fentanyl contamination of cocaine has contributed to a surge in opioid-involved overdose deaths among people who use cocaine (PWUC). Existing harm reduction strategies, including naloxone distribution, drug checking, and counseling people to use with others, are inadequate in fully addressing this risk. Despite robust evidence supporting contingency management (CM) as an effective treatment for cocaine use disorder (CUD), its implementation remains limited. Naltrexone, a potent opioid antagonist, has been evaluated for treatment of CUD and has not been found to be effective. No pharmacotherapies are FDA approved for CUD. However, naltrexone may provide opioid overdose protection for individuals at risk of unwitting fentanyl exposure through fentanyl contamination of cocaine. CASE PRESENTATION: We conducted a retrospective case series of three adults with cocaine use disorder receiving care at the Stimulant Treatment and Recovery Team (START) Clinic at Boston Medical Center. All three patients with cocaine use disorder reported cocaine use with unintentional fentanyl exposure, and two had prior nonfatal opioid-involved overdoses. Oral or intramuscular naltrexone was initiated in all cases and was tolerated without reported adverse effects or precipitated withdrawal. Patients continued naltrexone for several months, and no opioid-involved overdoses were reported.
conclusionsIn this case series of patients with cocaine use disorder, the initiation of naltrexone for opioid overdose risk prevention was feasible, acceptable, and well tolerated. Naltrexone warrants study as a component of overdose prevention strategies in stimulant treatment settings where fentanyl contamination poses increased risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.